BioSpace News Archive

Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada, Mexico, and select South American Countries.

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports.

Pre-clinical proof-of-concept demonstrated in a disease model.

CivicaScriptTM, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and EmsanaRx, PBC, the only pharmacy benefit manager built by employers, for employers, announced that EmsanaRx is joining CivicaScript as a partnering member.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system.

Prolacta Bioscience® announced the introduction of the first evidence-based feeding protocol for the use of an Exclusive Human Milk Diet including Prolacta’s products in the neonatal intensive care unit.

Propanc Biopharma, Inc. announced that the Company’s lead product candidate, PRP, targets solid tumors, which accounts for 80 – 90% of cancer cases, according to the National Cancer Institute.

Columbia University Irving Medical Center joins n-Lorem to facilitate ASO treatment for advance understanding of and improve healthcare for nano-rare patients.

Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company’s independent accountant to audit the balance sheet of the Company as of December 31, 2021.